玻璃体腔内注射康柏西普治疗白内障术后黄斑囊样水肿临床疗效观察
|
摘要
目的探讨康柏西普玻璃体腔内注射治疗白内障术后黄斑囊样水肿(CME)的临床效果。方法选取北京老年医院自2015年11月至2018年6月行超声乳化联合人工晶状体植入术后出现CME的老年性白内障患者16例(16眼)为研究对象。玻璃体腔内注射康柏西普0.05 ml,观察治疗前及治疗后1 d及1、2、4周的最佳矫正视力和黄斑中心凹厚度的改变情况。结果所有患者治疗后无并发症发生。与治疗前比较,视力在治疗后1 d及1、2、4周时均提高,黄斑中心凹厚度下降,差异均有统计学意义(P<0.05),但在治疗后4周时其厚度又稍有增加。结论玻璃体腔内注射康柏西普治疗白内障超声乳化联合人工晶状体植入手术后的CME,安全性高,起效时间短,可降低黄斑区视网膜厚度,提高视力。
Objective To investigate the therapeutic effect of intravitreal injection of conbercept on cystoid macular edema(CME) after phacoemulsification surgery.Methods A retrospective study was performed on 16 cases(16 eyes) of patients with CME after phacoemulsification surgery who were admitted from November 2015 to June 2018.Intravitreal injection of conbercept 0.05 ml was used to observe the changes of the best corrected visual acuity(BCVA) and the central fovea thickness(CFT) 1 day and 1,2,4 weeks before and after treatment.Results No complications occurred in all patients after treatment.Compared with before treatment,BCVA increased and CFT reduced in 1 day,1 week 2 weeks,4 weeks after treatment(P<0.05),while CFT was increased in the 4 weeks.Conclusion CME after phacoemulsification treated by intravitreal injection of conbercept combined with intraocular lens implantation has high safety and short onset time,which can reduce central fovea thickness and improve vision.
Objective To investigate the therapeutic effect of intravitreal injection of conbercept on cystoid macular edema(CME) after phacoemulsification surgery.Methods A retrospective study was performed on 16 cases(16 eyes) of patients with CME after phacoemulsification surgery who were admitted from November 2015 to June 2018.Intravitreal injection of conbercept 0.05 ml was used to observe the changes of the best corrected visual acuity(BCVA) and the central fovea thickness(CFT) 1 day and 1,2,4 weeks before and after treatment.Results No complications occurred in all patients after treatment.Compared with before treatment,BCVA increased and CFT reduced in 1 day,1 week 2 weeks,4 weeks after treatment(P<0.05),while CFT was increased in the 4 weeks.Conclusion CME after phacoemulsification treated by intravitreal injection of conbercept combined with intraocular lens implantation has high safety and short onset time,which can reduce central fovea thickness and improve vision.
引文
[1] Agarwal A,Afridi R,Hassan M.Novel therapies in development for diabetic macular edema[J].Curr Diab Rep,2015,15(10):74-86.
[2] Querques G,Iaculli C,Delle Noci N.Intravitreal pegaptanib sodium for irvine-gass syndrome[J].Eur J Ophthalmol,2008,18(1):138-141.
[3] Cohen SY,Nghiem-Buffet S,Grenet T,et al.Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab[J].Jpn J Ophlllalmol,2015,59(1):36-42.
[4] 余岚,陈长征,易佐慧子,等.玻璃体腔注射康柏西普治疗渗出型老年性黄斑变性的疗效观察[J].中华眼底病杂志,2015,31(3):256-259.
[5] 苏盈盈,钱芳,陈晓勇,等.糖尿病与非糖尿病患者白内障术后黄斑水肿分析[J].中国实用眼科杂志,2014,32(11):1281-1284.
[6] 李恒健,魏莉,吕绍成.康柏西普治疗视网膜中央静脉阻塞的临床观察[J].临床眼科杂志,2017,25(1):70-71.
[7] 葛庆曼,解孝锋.玻璃体腔注射康柏西普治疗糖皮质激素治疗无效的Ⅱ型视盘血管炎继发黄斑水肿的疗效观察[J].中华眼科医学杂志,2016,6(1):19-25.
[8] 梁婧,张黎,佘兮.玻璃体腔注射康柏西普联合Ahmed青光眼阀植入和全视网膜光凝治疗有视功能新生血管性青光眼[J].国际眼科杂志,2016,16(9):1740-1742.
[9] 修立恒,李佳林,李常栋,等.玻璃体内注射雷珠单抗治疗病理性近视合并脉络膜新生血管疗效观察[J].眼科新进展,2015,35(11):1067-1070.
[10] 石蕊,杨乐,齐赟,等.康柏西普和雷珠单抗治疗黄斑水肿有效性的Meta分析[J].国际眼科杂志,2017,17(12):2242-2247.
[11] Li X,Xu G,Wang Y,et al.Safety and efficacy of conbercepr in neovascular age-rated macular degeneration:results from a 12-month randomized phase 2 study:AURORA study[J].Ophthalmology,2014,121(9):1740-1747.
[2] Querques G,Iaculli C,Delle Noci N.Intravitreal pegaptanib sodium for irvine-gass syndrome[J].Eur J Ophthalmol,2008,18(1):138-141.
[3] Cohen SY,Nghiem-Buffet S,Grenet T,et al.Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab[J].Jpn J Ophlllalmol,2015,59(1):36-42.
[4] 余岚,陈长征,易佐慧子,等.玻璃体腔注射康柏西普治疗渗出型老年性黄斑变性的疗效观察[J].中华眼底病杂志,2015,31(3):256-259.
[5] 苏盈盈,钱芳,陈晓勇,等.糖尿病与非糖尿病患者白内障术后黄斑水肿分析[J].中国实用眼科杂志,2014,32(11):1281-1284.
[6] 李恒健,魏莉,吕绍成.康柏西普治疗视网膜中央静脉阻塞的临床观察[J].临床眼科杂志,2017,25(1):70-71.
[7] 葛庆曼,解孝锋.玻璃体腔注射康柏西普治疗糖皮质激素治疗无效的Ⅱ型视盘血管炎继发黄斑水肿的疗效观察[J].中华眼科医学杂志,2016,6(1):19-25.
[8] 梁婧,张黎,佘兮.玻璃体腔注射康柏西普联合Ahmed青光眼阀植入和全视网膜光凝治疗有视功能新生血管性青光眼[J].国际眼科杂志,2016,16(9):1740-1742.
[9] 修立恒,李佳林,李常栋,等.玻璃体内注射雷珠单抗治疗病理性近视合并脉络膜新生血管疗效观察[J].眼科新进展,2015,35(11):1067-1070.
[10] 石蕊,杨乐,齐赟,等.康柏西普和雷珠单抗治疗黄斑水肿有效性的Meta分析[J].国际眼科杂志,2017,17(12):2242-2247.
[11] Li X,Xu G,Wang Y,et al.Safety and efficacy of conbercepr in neovascular age-rated macular degeneration:results from a 12-month randomized phase 2 study:AURORA study[J].Ophthalmology,2014,121(9):1740-1747.